FDA Approves Enspryng for At-Home Treatment of Thyroid Eye Disease

The U.S. Food and Drug Administration (FDA) has approved Enspryng (satralizumab) as the first and only at-home subcutaneous treatment option for adults with thyroid eye disease (TED). This regulatory action provides a new, convenient treatment alternative for patients, allowing for self-administration or administration by a caregiver after training.